Fresenius Kabi AG：市場シェア分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 5
2 Introduction 6
2.1 What Is This Report About? 6
3 Definitions of Markets/Categories Covered 7
3.1 Drug Delivery Devices 7
3.1.1 Infusion Systems 7
4 Company Snapshot 8
4.1 Key Facts 8
4.2 Company Overview 8
4.3 SWOT Snapshot 8
4.4 Business Overview 9
4.5 Major Products and Services 10
4.5.1 Overview 10
5 History 14
6 SWOT Analysis 16
6.1 Overview 16
6.2 Fresenius Kabi AG Strengths 16
6.2.1 Market Position 16
6.2.2 Range of Products 16
6.2.3 Operational Base 17
6.3 Fresenius Kabi AG Weaknesses 17
6.3.1 Quality Issues 17
6.4 Fresenius Kabi AG Opportunities 18
6.4.1 Expansion Plan 18
6.4.2 Global Hospital Supplies Market 18
6.4.3 Rising Healthcare Expenditure 18
6.5 Fresenius Kabi AG Threats 19
6.5.1 Competitive Environment 19
6.5.2 Pressure Due to Regulations 19
6.5.3 Uncertain R&D Outcomes 19
7 Competitors 20
8 Competitive Landscape 21
8.1 Drug Delivery Devices (Infusion Systems), Global, Market Share (%), 2011 21
8.2 Fresenius Kabi AG, Drug Delivery Devices (Infusion Systems), by Region, Market Share (2011) 23
8.3 Fresenius Kabi AG, Drug Delivery Devices (Infusion Systems), by Country, Market Share (2011) 24
9 Key Employees 26
10 Key Employee Biographies 27
11 Company Statement 28
12 Locations And Subsidiaries 29
12.1 Head Office 29
12.2 Other Locations & Subsidiaries 29
13 Fresenius Kabi AG Detailed Deal Summary 32
13.1 Acquisition 32
13.1.1 Fresenius Kabi Completes Acquisition Of Fenwal From TPG Capital And Maverick Capital For $1.1 Billion 32
13.1.2 Fresenius Kabi Acquires Remaining JV Stake In Pharmatel Fresenius Kabi From Pharmatel 34
14 Recent Developments 35
14.1 Strategy And Business Planning 35
14.1.1 Oct 29, 2009: Octapharma Seals License, Development, Supply Agreement With Fresenius Kabi 35
14.2 Corporate Communications 35
14.2.1 Dec 02, 2011: Fresenius Kabi Announces Management Board Changes 35
14.3 Legal and Regulatory 37
14.3.1 Feb 24, 2012: APP Pharma Receives FDA Warning Letter Regarding Grand Island Plant 37
14.4 Product News 37
14.4.1 Oct 18, 2010: FDA Announces Class I Recall Of Fresenius Kabi’s Red Blood Cell (RBC) Exchange Sets Used On AS104 Blood Cell Separation Devices 37
15 Appendix 38
15.1 Research Methodology 39
15.2 Secondary Research 39
15.3 Primary Research 39
15.4 Models 40
15.5 Forecasts 40
15.6 Expert Panels 40
15.7 GlobalData Consulting 40
15.8 Currency Conversion 41
15.9 Contact Us 42
15.10 Disclaimer 42